First Trust Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding CPRX
VCM
DM
VPM
First Trust Advisors's CPRX Position: Q1 2026 in Review
First Trust Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 279% in Q1 2026, buying an estimated $6.07M and bringing the position to 346,244 shares worth $8.57M. The position accounts for 0.01% of the portfolio, ranked #1166.
First Trust Advisors first reported a position in CPRX in Q3 2020 and has held it in 21 quarters since. The position peaked at $48.3M in Q3 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- First Trust Advisors held 346,244 shares of Catalyst Pharmaceutical worth $8.57M as of Q1 2026.
- First Trust Advisors bought 254,902 Catalyst Pharmaceutical shares in Q1 2026, an estimated $6.07M.
- Catalyst Pharmaceutical made up 0.01% of First Trust Advisors's portfolio in Q1 2026, its #1166 holding.
- First Trust Advisors first reported a position in Catalyst Pharmaceutical in Q3 2020 and has held it in 21 quarters since.
- First Trust Advisors's Catalyst Pharmaceutical position peaked at $48.3M in Q3 2024.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.